Donanemab in early symptomatic Alzheimer’s disease: results from the TRAILBLAZER-ALZ 2 long-term extension

Puntos clave

• Donanemab slows cognitive decline in patients with early symptomatic Alzheimer's disease, potentially aiding treatment strategies.
• Long-term extension data from TRAILBLAZER-ALZ 2 shows continued treatment effects over time, emphasizing sustainability of intervention.
• Analysis of the trial's extension phase highlights the treatment's efficacy in reducing symptoms in Alzheimer's disease barriers to progress.
• Further validation of these findings is warranted to strengthen the case for donanemab as a viable therapy option.